Who We Are

We are the first and only clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S.* that is discovering and developing innovative drugs for indications with significant unmet medical needs and large market opportunities. We were founded in 2007 with the establishment of US Sirnaomics in Gaithersburg, Maryland. We are the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for our core product, STP705.

Our product pipeline is deep as it has broad therapeutic utility across rare and large market diseases including oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. We now have 5 ongoing clinical trials in phase I/II stage and another at least 14 other product candidates in IND enabling or advanced preclinical studies.

Our proprietary delivery platforms for administration of RNA-based therapeutics are the foundation of our product pipeline, including our polypeptide nanoparticle (PNP) delivery platform optimizable for local or systemic administration of RNAi therapeutics and targets beyond liver hepatocyte cells, our GalNAc-based delivery platforms for systemic administration and liver-targeting RNAi therapeutics, and our polypeptide lipid nanoparticle (PLNP) delivery platform useful for administration of mRNA vaccines and therapeutics.

map map
Boston – BD center
Beijing – China Clinical Center
Suzhou – China Headquarter, R&D Hub
Guangzhou – Manufacturing Facility
Hong Kong – Financing & IR
Laguna Niguel, CA – US Clinical Center
Gaithersburg – Global Headquarter

Leadership Team

Dr. Patrick Y. Lu
Chairman of the Board, Executive Director, President & Chief Executive Officer
Dr. Michael V. Molyneaux
Executive Director, Chief Medical Officer
Dr. David Mark Evans
Executive Director and Chief Scientific Officer
Dr. Steven Z. Long
Chief Development Officer
Dr. Dmitry Samarsky
Chief Technology Officer
Dr. Edward Yongxiang Wang
Chief Production Officer
Dr. Richard W. Welch
Vice President, CMC
Dr. John Xu
VP Pre-clinical Studies, General Manager of Suzhou Sirnaomics
Mr. Wing Kei Yip (Nigel)
Vice President of Corporate Finance, China Chief Financial Officer
Ms. Yun Zhang (Monica)
China Chief Operating Officer, Board Secretary, Joint Company Secretary
Mr. George Ji
Chief Operation Officer
Mr. John Buergenthal
Vice President, Human Resources

Our Story

KEY BUSINESS MILESTONES

2021

Established co-development partnership with Walvax to license out the China rights of  STP702

Completed Series E financing raising approximately US$106.7 million

Initiated Phase IIb study for STP705 for isSCC in the U.S.

Initiated Phase II clinical trial for STP705 for Keloid scarless healing in the U.S.

Initiated Phase I clinical trial for STP705 for live cancer in the U.S.

Obtained acceptance for review for STP705 for isSCC from NMPA

Obtained IND clearance for STP707 from FDA

Completed the overall construction and acceptance of the pilot production plant of  polypeptide nanoparticle nucleic acid drugs in Sirnaomics Guangzhou and entered into the trial operation stage

Started the construction of Southern Headquarters of Sirnaomics, which is expected to be completed in 2021 

2020

Commencement of operation of RNAimmune

Completed Series D financing raising approximately US$104 million

Completed Phase I/II study for STP705 for isSCC in the U.S.

Initiated Phase II clinical trial for STP705 for BCC in the U.S.

2019

Completed Series C financing raising US$48 million

Set up Sirnaomics Hong Kong

2017

Completed Series B financing raising US$10 million

Achieved the first IND approval ofRNAi drug for STP705 treating HTS

Guangzhou Sirnaomics obtained the national innovation company certification

Guangzhou Sirnaomics and Jiangsu Zhengyuan started cooperation to develop a variety of atomization drug delivery devices

2016

Obtained IND clearance for STP705 for hypertrophic scar from FDA

2015

Suzhou Sirnaomics and Guangzhou Sirnaomics were selected as the “Significant New Drug Creation” in the 13th Five-Year Plan

2014

Submitted to CFDA the IND application for China's first nucleic acid drug-STP705 for the treatment of hypertrophic scars

2013

Suzhou Sirnaomics and Guangzhou Sirnaomics were selected as the “Significant New Drug Creation” in the 12th Five-Year Plan

2012

Established Guangzhou Sirnaomics

Guangzhou Sirnaomics was selected as Guangzhou Entrepreneurship Leading Talent Project

2009

Suzhou Sirnaomics was selected as Jiangsu Science and Technology Leading Talent Project

Suzhou Sirnaomics was certified as Suzhou Engineering Research Center for nucleic acid drugs by Suzhou Science and Technology Bureau

2008

Established Suzhou Sirnaomics

2007

Established US Sirnaomics

Patent
Our patents and patent applications span methods of delivering RNAi triggers and mRNA to cells, compositions of matter and devices used in our RNAi and mRNA delivery platforms, siRNA or RNAi trigger compositions, manufacturing processes, usage and indications. We owned
img

9issued patents in China

img

9issued patents in the U.S.

img

2issued patents in Europe (validated in 11 and 8 countries, respectively),

img

119pending patent applications, including 19 Chinese patent applications, 43 U.S. patent applications (including 32 U.S. provisional patent applications), 8 patent applications under the Patent Cooperation Treaty, 6 patent applications in Europe and 43 patent applications in other jurisdictions.

Contact Us
Sirnaomics, Inc.

401 Professional Dr, STE 280 Gaithersburg, MD 20879, USA

+1 301-740-1730
Sirnaomics, Suzhou

218 Xinghu Street, STE A4-415 BioBay, Suzhou, CHINA

+86 512 62956283
Sirnaomics, Guangzhou

12 Luoxuan 3 Road, STE 4-306 Guangzhou International Bio-island Guangzhou, CHINA

+86 20 84229842
Sirnaomics, Hong Kong

46/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong

+852 3180 9494
Sirnaomics, Boston Office

245 First Street, 18F
Cambridge, MA 02142, USA

+1 508-517-7566